Abstract
The pathogenesis of depression is complex involving the interplay of genetic and environmental risk factors including diet, lifestyle and the gut microbiome. Metabolomics studies may shed light on the interplay of these factors. We study over 63,000 individuals including 8462 cases with a lifetime major depression and 5403 cases with recurrent major depression from the UK Biobank profiled for nuclear magnetic resonance (NMR) spectroscopy based metabolites with the Nightingale platform. We identify 124 metabolites that are associated with major depressive disorder (MDD), including 49 novel associations. No differences were seen between the metabolic profiles of lifetime and recurrent MDD. We find that metabolites involved in the tricarboxylic acid (TCA) cycle are significantly altered in patients with MDD. Integrating the metabolic signatures of major depression and the gut microbiome, we find that the gut microbiome might play an important role in the relationship between these metabolites, lipoproteins in particular, and MDD. The order Clostridiales, and the phyla Proteobacteria and Bacteroidetes were the most important taxa, which link the lipoprotein particles to MDD. Our study shows that at the molecular level energy metabolism is disturbed in patients with MDD and that the interplay between the gut microbiome and blood metabolome may play a key role in the pathogenesis of MDD.
Competing Interest Statement
Dr. Kaddurah-Daouk in an inventor on a series of patents on use of metabolomics for the diagnosis and treatment of CNS diseases and holds equity in Metabolon Inc., Chymia LLC and PsyProtix. Alternatively, R.K-D. formed Chymia LLC and PsyProtix, a Duke University biotechnology spinout aiming to transform the treatment of mental health disorders. All other authors declare no conflicts of interest. Dr. Saykin receives support from multiple NIH grants (P30 AG010133, P30 AG072976, R01 AG019771, R01 AG057739, U01 AG024904, R01 LM013463, R01 AG068193, T32 AG071444, and U01 AG068057 and U01 AG072177). He has also received support from Avid Radiopharmaceuticals, a subsidiary of Eli Lilly (in kind contribution of PET tracer precursor); Bayer Oncology (Scientific Advisory Board); Eisai (Scientific Advisory Board); Siemens Medical Solutions USA, Inc. (Dementia Advisory Board); Springer-Nature Publishing (Editorial Office Support as Editor-in-Chief, Brain Imaging and Behavior). M.A. and G.K. received funding (through their institutions) from the National Institutes of Health/National Institute on Aging through grants RF1AG058942, RF1AG059093, U01AG061359, U19AG063744, and R01AG069901. M.A. and G.K. are co-inventors (through Duke University/Helmholtz Zentrum Munchen) on patents on applications of metabolomics in diseases of the central nervous system; M.A. and G.K. hold equity in Chymia LLC and IP in PsyProtix and Atai that are exploring the potential for therapeutic applications targeting mitochondrial metabolism in treatment-resistant depression.
Funding Statement
Metabolomics data is provided by the Alzheimers disease Metabolomics Consortium (ADMC) and funded wholly or in part by the following grants and supplements thereto: NIA R01AG046171, RF1AG051550, RF1AG057452, R01AG059093, RF1AG058942, U01AG061359, U19AG063744 and FNIH: DAOU16AMPA awarded to Dr. Kaddurah-Daouk at Duke University in partnership with a large number of academic institutions. As such, the investigators within the ADMC, not listed specifically in this publication authors list, provided data along with its pre-processing and prepared it for analysis, but did not participate in analysis or writing of this manuscript. A complete listing of ADMC investigators can be found at: https://sites.duke.edu/adnimetab/team/. In order to accurately acknowledge data gathering and pre-processing by the ADMC, data users must include a laboratory specific acknowledgement statement in the methods section of manuscripts. These study/dataset-specific acknowledgements can be found in the Study Pages. Depending upon the length and focus of the article, it may be appropriate to include more or less of these statements. The Nightingale datasets have been generated at Nightingale Health.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
UK Biobank has approval from the Northwest Multi-centre Research Ethics Committee, the Patient Information Advisory Group, and the Community Health Index Advisory Group.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, University of Washington, and Vrije Universiteit Amsterdam.